Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25491822 |
US |
30 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 2 | 25491827 |
US |
60 | 2 |
Limb injury, Accidental exposure to product, Device difficult to use, Injection site erythema, Injection site haemorrhage, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 3 | 25491871 |
US |
85 | 2 |
Wrong technique in device usage process, Product dose omission issue, Accidental exposure to product, |
||||
BELIMUMAB, |
||||
| 4 | 25492309 |
GB |
||
Device breakage, Accidental exposure to product, |
||||
| 5 | 25492320 |
US |
1 | |
Accidental exposure to product, |
||||
AZELASTINE HYDROCHLORIDE, AZELASTINE, |
||||
| 6 | 25492607 |
CN |
||
Accidental exposure to product, Device leakage, |
||||
GUSELKUMAB, |
||||
| 7 | 25492855 |
US |
2 | |
Device defective, Incorrect dose administered by device, Needle issue, Accidental exposure to product, |
||||
METHOTREXATE, METHOTREXATE SODIUM, FOLIC ACID, |
||||
| 8 | 25493394 |
US |
71 | 1 |
Road traffic accident, Device difficult to use, Accidental exposure to product, Drug dose omission by device, Product communication issue, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 9 | 25493411 |
US |
2 | |
Incorrect dose administered, Accidental exposure to product, Product delivery mechanism issue, |
||||
AZELASTINE HYDROCHLORIDE, AZELASTINE, |
||||
| 10 | 25493514 |
US |
2 | |
Accidental exposure to product, Wrong technique in product usage process, |
||||
FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 11 | 25493833 |
US |
1 | |
Device malfunction, Complication of device insertion, Accidental exposure to product, Device leakage, Drug dose omission by device, |
||||
OFATUMUMAB, LEVOTHYROXINE SODIUM, |
||||
| 12 | 25494150 |
US |
2 | |
Sensory disturbance, Injury associated with device, Wrong patient received product, Accidental exposure to product, Device use error, Injection site pain, Injection site swelling, |
||||
EVOLOCUMAB, |
||||
| 13 | 25494656 |
US |
56 | 2 |
Exposure via skin contact, Injection site haemorrhage, Wrong technique in device usage process, Accidental exposure to product, Incorrect dose administered, |
||||
BELIMUMAB, |
||||
| 14 | 25494791 |
US |
60 | 2 |
Accidental exposure to product, Product dose omission issue, Device issue, |
||||
GUSELKUMAB, |
||||
| 15 | 25495232 |
US |
2 | |
Device issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 16 | 25495566 |
US |
83 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 17 | 25495598 |
US |
58 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 18 | 25495703 |
US |
50 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 19 | 25495704 |
US |
61 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 20 | 25495708 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 21 | 25495727 |
US |
70 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 22 | 25495784 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 23 | 25495787 |
US |
82 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 24 | 25495796 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 25 | 25495834 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 26 | 25495840 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 27 | 25496060 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 28 | 25490969 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 29 | 25491071 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 30 | 25491227 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 31 | 25491369 |
US |
60 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 32 | 25491452 |
CH |
1 | |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 33 | 25491489 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 34 | 25491616 |
US |
12 | 2 |
Injection site discharge, Accidental exposure to product, Incorrect dose administered, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 35 | 25489953 |
US |
61 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 36 | 25490022 |
US |
54 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 37 | 25490153 |
US |
61 | 2 |
Accidental exposure to product, Device difficult to use, Drug dose omission by device, Injection site pain, |
||||
ETANERCEPT, |
||||
| 38 | 25490273 |
US |
27 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 39 | 25490274 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 40 | 25490280 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 41 | 25490287 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 42 | 25490361 |
US |
52 | 2 |
Rash, Underdose, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 43 | 25490371 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 44 | 25486442 |
US |
61 | 2 |
Ocular discomfort, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 45 | 25486455 |
US |
42 | 2 |
Device malfunction, Accidental exposure to product, Device leakage, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 46 | 25486479 |
US |
74 | |
Rash, Pruritus, Device difficult to use, Accidental exposure to product, Rubber sensitivity, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 47 | 25486626 |
US |
61 | 1 |
Injection site pain, Device difficult to use, Accidental exposure to product, Incorrect dose administered by device, |
||||
EVOLOCUMAB, |
||||
| 48 | 25486810 |
US |
76 | |
Needle issue, Accidental exposure to product, Incorrect dose administered, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 49 | 25487817 |
US |
||
Product dose omission issue, Drug delivery system malfunction, Accidental exposure to product, |
||||
GOLIMUMAB, |
||||
| 50 | 25487828 |
US |
71 | 1 |
Product dose omission issue, Needle issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 51 | 25489017 |
US |
53 | 2 |
Eye irritation, Bacterial rhinitis, Eye discharge, Ocular discomfort, Product dose omission issue, Accidental exposure to product, Device defective, Device issue, |
||||
OMALIZUMAB, ETANERCEPT, ETANERCEPT, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, TIRZEPATIDE, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, HYDROXYZINE, |
||||
| 52 | 25489128 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 53 | 25489135 |
US |
74 | 1 |
Hypoacusis, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 54 | 25489137 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 55 | 25489179 |
US |
14 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 56 | 25489192 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 57 | 25489220 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 58 | 25489368 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 59 | 25489384 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 60 | 25489390 |
US |
70 | 1 |
Product dispensing error, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 61 | 25489475 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 62 | 25489481 |
US |
46 | 1 |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
INSULIN GLARGINE, |
||||
| 63 | 25489497 |
US |
7 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 64 | 25490504 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 65 | 25490570 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 66 | 25490781 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 67 | 25490804 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 68 | 25490829 |
US |
9 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 69 | 25481256 |
US |
2 | |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Underdose, Product complaint, |
||||
BELIMUMAB, |
||||
| 70 | 25481352 |
US |
29 | 1 |
Accidental exposure to product, Wrong technique in device usage process, |
||||
BELIMUMAB, |
||||
| 71 | 25481403 |
US |
1 | |
Needle issue, Accidental exposure to product, Drug dose omission by device, |
||||
| 72 | 25481681 |
US |
70 | 1 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 73 | 25481718 |
US |
33 | 2 |
Injection site haemorrhage, Accidental exposure to product, Device malfunction, |
||||
FREMANEZUMAB-VFRM, |
||||
| 74 | 25481814 |
US |
1 | |
Accidental exposure to product, Injection site pain, |
||||
| 75 | 25482506 |
US |
42 | 2 |
Product dose omission issue, Needle issue, Product complaint, Accidental exposure to product, Product closure issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 76 | 25482585 |
US |
2 | |
Accidental exposure to product, Accidental underdose, Device defective, No adverse event, |
||||
OMALIZUMAB, |
||||
| 77 | 25483101 |
US |
1 | |
Device malfunction, Needle issue, Accidental exposure to product, |
||||
OFATUMUMAB, |
||||
| 78 | 25483434 |
US |
69 | 2 |
Injection site pain, Injection site bruising, Injection site haemorrhage, Device difficult to use, Accidental exposure to product, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 79 | 25483764 |
US |
76 | 1 |
Drug effect less than expected, Accidental exposure to product, Inappropriate schedule of product administration, |
||||
DICLOFENAC SODIUM, |
||||
| 80 | 25484008 |
US |
2 | |
Accidental exposure to product, Incorrect dose administered by device, |
||||
ESKETAMINE HYDROCHLORIDE, ESKETAMINE HYDROCHLORIDE, ESKETAMINE HYDROCHLORIDE, |
||||
| 81 | 25484118 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 82 | 25484238 |
US |
19 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 83 | 25484297 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 84 | 25484357 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 85 | 25484373 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 86 | 25484382 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 87 | 25484415 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 88 | 25484426 |
US |
69 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 89 | 25484429 |
US |
26 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 90 | 25484770 |
US |
47 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 91 | 25485171 |
CA |
53 | 2 |
Device deployment issue, Product dose omission issue, Accidental exposure to product, |
||||
GOLIMUMAB, |
||||
| 92 | 25485485 |
US |
1 | |
Injury associated with device, Accidental exposure to product, Device use error, |
||||
EVOLOCUMAB, |
||||
| 93 | 25486249 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 94 | 25486286 |
US |
51 | 2 |
Needle issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 95 | 25486317 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, OCTOCRYLENE, AVOBENZONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, MOMETASONE FUROATE, MOMETASONE, |
||||
| 96 | 25475939 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 97 | 25476095 |
US |
2 | |
Device issue, Injection site haemorrhage, Accidental exposure to product, Incorrect dose administered by device, Device leakage, |
||||
OFATUMUMAB, |
||||
| 98 | 25476422 |
US |
47 | 2 |
Accidental exposure to product, Underdose, |
||||
GALCANEZUMAB-GNLM, EPINEPHRINE, |
||||
| 99 | 25477266 |
US |
||
Accidental exposure to product, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, |
||||
| 100 | 25477366 |
US |
2 | |
Condition aggravated, Device leakage, Accidental exposure to product, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-07-29